Revelation Pharma Acquires Cascade Pharmacy, Boosting Animal Health Initiatives Alongside Phibro Animal Health

Revelation Pharma Expands Animal Health Capabilities with Acquisition of Cascade Specialty Pharmacy

Revelation Pharma, a national leader in the compounding pharmacy sector, announces its acquisition of Cascade Specialty Pharmacy, located in Washington. This strategic move significantly expands Revelation's footprint in the western and northwestern regions of the United States, particularly enhancing its offerings in both Ear, Nose, and Throat (ENT) and animal health compounding. Shawn Hodges, CEO of Revelation Pharma, underscores the importance of this acquisition, stating that it aligns with the company's commitment to maintaining high standards in patient care while reinforcing its dedication to the animal health sector.

Cascade Specialty Pharmacy will maintain its current operations, ensuring that existing customers benefit from the new fulfillment options and an expanded product range. Among these offerings are the CSalts, which are medicated salt packets designed specifically for sinus irrigation, exemplifying the innovative solutions that Revelation aims to provide. Brandon Knott, the former owner of Cascade, shares his confidence that Revelation’s resources and expertise will enhance Cascade’s mission, while he will continue to lend his expertise as an ENT Allergy Product Specialist. This continuity is crucial, as it allows for a seamless transition that prioritizes patient care and satisfaction.

The acquisition reflects a broader strategy by Revelation Pharma to bolster its capabilities and offerings across both human and animal health sectors. As the pharmacy network expands, the integration of new services—such as virtual telemedicine—demonstrates a commitment to personalized pharmaceutical preparations. Angela Williams, the Pharmacist In Charge at Cascade, expresses enthusiasm about the collaboration, highlighting the potential for innovation and growth in the compounding industry. This strategic alignment not only enhances the range of compounded medications available but aims to elevate the overall service capabilities of Revelation Pharma, positioning it well to meet the diverse needs of communities across the country.

In parallel, Phibro Animal Health Corporation is preparing to release its second-quarter financial results on February 5, 2025. The company plans to host a conference call on February 6, 2025, to discuss these results. As a prominent player in the animal health and mineral nutrition sector, Phibro emphasizes its commitment to improving the well-being of both livestock and companion animals through innovative solutions.

As Revelation Pharma solidifies its position in the compounding pharmacy landscape, the company’s focus on enhancing animal health solutions aligns perfectly with the ongoing efforts of industry players like Phibro Animal Health. Both companies are dedicated to serving their communities and ensuring high standards in animal care, reflecting a shared commitment to advancing the health and welfare of animals.